Uncategorized
FDA approves Eylea to treat diabetic retinopathy in patients with diabetic macular edema
The FDA has approved Eylea injection to treat diabetic retinopathy in diabetic macular edema patients, according to an agency press release.Two clinical studies evaluated the safety and efficacy of Eylea (aflibercept, Regeneron) vs. macular laser photocoagulation in 679 patients, with results showing significant improvement in the severity of diabetic retinopathy at 100 weeks after Eylea injection compared with laser, the release said.